Phil A Crosbie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1888550/publications.pdf

Version: 2024-02-01

38	5,995	304743	315739
papers	citations	22 h-index	38 g-index

39	39	39	11361
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules. Thorax, 2022, 77, 988-996.	5.6	4
2	Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling. Health Technology Assessment, 2022, 26, 1-180.	2.8	0
3	Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. Journal of Medical Genetics, 2021, 58, 217-226.	3.2	15
4	Performance monitoring of EBUS for the staging and diagnosis of lung cancer: auditing the Greater Manchester EBUS service against new national standards. BMJ Open Respiratory Research, 2021, 8, e000777.	3.0	3
5	Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. BMJ Open, 2020, 10, e037075.	1.9	48
6	Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. BMJ Open, 2020, 10, e037086.	1.9	31
7	Analysis of lung cancer risk model (PLCO_{M2012} and LLP_{v2}) performance in a community-based lung cancer screening programme. Thorax, 2020, 75, 661-668.	5.6	28
8	Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD. Thorax, 2020, 75, 655-660.	5.6	28
9	Implementation and outcomes of the RAPID programme: Addressing the front end of the lung cancer pathway in Manchester. Clinical Medicine, 2020, 20, 401-405.	1.9	12
10	Top ten research priorities for detecting cancer early. Lancet Public Health, The, 2019, 4, e551.	10.0	45
11	CT screening for lung cancer: Are we ready to implement in Europe?. Lung Cancer, 2019, 134, 25-33.	2.0	25
12	Attendees of Manchesterâ€™s Lung Health Check pilot express a preference for community-based lung cancer screening. Thorax, 2019, 74, 1176-1178.	5.6	16
13	Second round results from the Manchester â€˜Lung Health Checkâ€™ community-based targeted lung cancer screening pilot. Thorax, 2019, 74, 700-704.	5.6	59
14	â€œTo know or not to knowâ€¦?â€•Push and pull in ever smokers lung screening uptake decisionâ€making intentions. Health Expectations, 2019, 22, 162-172.	2.6	16
15	Implementing lung cancer screening: baseline results from a community-based â€˜Lung Health Checkâ€™ pilot in deprived areas of Manchester. Thorax, 2019, 74, 405-409.	5.6	163
16	The cost-effectiveness of the Manchester â€˜lung health checksâ€™, a community-based lung cancer low-dose CT screening pilot. Lung Cancer, 2018, 126, 119-124.	2.0	30
17	Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. Lung Cancer, 2018, 124, 148-153.	2.0	27
18	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323

#	Article	IF	Citations
19	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
20	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	27.0	1,786
21	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
22	Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. Journal of Thoracic Oncology, 2016, 11, 1793-1797.	1.1	80
23	Should All Lung Cancer Patients Requiring Mediastinal Staging With EBUS Undergo PET-CT First?. Journal of Bronchology and Interventional Pulmonology, 2015, 22, e5-e7.	1.4	4
24	Can EBUS-TBNA Provide an Accurate Diagnosis in Patients Found to Have Enlarged or FDG-avid Lymph Nodes During Surveillance of Previously Treated Lung Cancer?. Journal of Bronchology and Interventional Pulmonology, 2015, 22, 114-120.	1.4	4
25	Pulmonary artery sarcoma: a rare thoracic tumor frequently misdiagnosed at presentation. Thoracic Cancer, 2015, 6, 797-799.	1.9	9
26	Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews, 2015, 41, 361-375.	7.7	142
27	Nodal Staging in Lung Cancer: A Risk Stratification Model for Lymph Nodes Classified as Negative by EBUS-TBNA. Journal of Thoracic Oncology, 2015, 10, 126-133.	1.1	40
28	Thoracic Metastasis From Renal Cell Carcinoma. Journal of Bronchology and Interventional Pulmonology, 2015, 22, 55-57.	1.4	3
29	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 2014, 12, e1001906.	5.6	185
30	EBUS-TBNA in Elderly Patients with Lung Cancer: Safety and Performance Outcomes. Journal of Thoracic Oncology, 2014, 9, 370-376.	1.1	39
31	The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treatment Reviews, 2014, 40, 558-566.	7.7	350
32	Cerebral air embolism following transbronchial lung biopsy during flexible bronchoscopy. Respiratory Medicine Case Reports, 2014, 12, 39-40.	0.4	9
33	Can Computed Tomography Characteristics Predict Outcomes in Patients Undergoing Radial Endobronchial Ultrasound-Guided Biopsy of Peripheral Lung Lesions?. Journal of Thoracic Oncology, 2014, 9, 1393-1397.	1.1	29
34	Topographical study of O6-alkylguanine DNA alkyltransferase repair activity and N7-methylguanine levels in resected lung tissue. Chemico-Biological Interactions, 2013, 204, 98-104.	4.0	7
35	Should we give long-term macrolide therapy for COPD?. Thorax, 2013, 68, 966-966.	5.6	1
36	Diagnosis of alveolar rhabdomyosarcoma in effusion cytology: a diagnostic pitfall. Cytopathology, 2010, 21, 273-275.	0.7	12

#	Article	IF	Citations
37	Long-term macrolide therapy in chronic inflammatory airway diseases. European Respiratory Journal, 2009, 33, 171-181.	6.7	122
38	Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O⁶â€alkylguanineâ€“DNA alkyltransferase. International Journal of Cancer, 2008, 122, 791-795.	5.1	21